NCT01713855View on ClinicalTrials.gov

Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura

NACompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 31, 2004

Study Completion Date

March 31, 2006

Conditions
Idiopathic Thrombocytopenic PurpuraImmune Thrombocytopenic Purpura
Interventions
BIOLOGICAL

Inactivated Trivalent Influenza vaccine

Trial Locations (3)

30322

Emory University School of Medicine, Atlanta

90095

University of California, Los Angeles, Los Angeles

02115

Children's Hospital, Boston

All Listed Sponsors
collaborator

Terrana ITP Research Fund

OTHER

lead

Neufeld, Ellis J, MD, PhD

INDIV

NCT01713855 - Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura | Biotech Hunter | Biotech Hunter